top of page

MicuRx’S Phase III MRSA antibiotic trial to support Chinese NDA filing

MicuRx has initiated patient enrolment in a Phase 3 study of MRX-I, an oral oxazolidinone antibacterial, in China for the treatment of complicated skin and skin structure infections (cSSSI). These infections are frequently caused by multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page